ALEXANDER SELIOUTSKI: Open Payments
NPI 1851360606 · MAYVILLE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$371 in 20 payments from 12 companies in 2025. Trend: 2023 $680 · 2024 $1,070 · 2025 $371
Food & beverage: $371
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $51 |
| Lilly USA, LLC | 3 | $49 |
| Novo Nordisk Inc | 2 | $44 |
| Boston Scientific Corporation | 2 | $44 |
| ABBVIE INC. | 2 | $36 |
| Amgen Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: TRELEGY ELLIPTA, WATCHMAN FLX, JARDIANCE, OTEZLA, Wegovy, Dexcom G6 Transmitter, FARXIGA, UBRELVY.
Industry payments across NY — which companies pay providers there.
